1
Xander, Nicolas S.H., Fiets, W. Edward, Uyl-de Groot, Carin A.
Veröffentlicht in: Xander , N S H , Fiets , W E & Uyl-de Groot , C A 2023 , ' Cost-effectiveness and budget impact of pembrolizumab+axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands ' , Frontiers in Oncology , vol. 13 , 1205700 . https://doi.org/10.3389/fonc.2023.1205700;
2023
Veröffentlicht in: Xander , N S H , Fiets , W E & Uyl-de Groot , C A 2023 , ' Cost-effectiveness and budget impact of pembrolizumab+axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands ' , Frontiers in Oncology , vol. 13 , 1205700 . https://doi.org/10.3389/fonc.2023.1205700;
2023
2
3
Leeneman, Brenda, Xander, Nicolas S.H., Fiets, W. Edward, de Jong, Wouter K., Uyl, Nathalie E.M., Wymenga, A. N.Machteld, Reyners, An K.L., Uyl-de Groot, Carin A.
Veröffentlicht in: Leeneman , B , Xander , N S H , Fiets , W E , de Jong , W K , Uyl , N E M , Wymenga , A N M , Reyners , A K L & Uyl-de Groot , C A 2024 , ' Assessing the clinical benefit of systemic anti-cancer treatments in the Netherlands : The impact of different thresholds for effectiveness ' , European Journal of Cancer , vol. 202 , 114002 . https://doi.org/10.1016/j.ejca.2024.114002;
2024
Veröffentlicht in: Leeneman , B , Xander , N S H , Fiets , W E , de Jong , W K , Uyl , N E M , Wymenga , A N M , Reyners , A K L & Uyl-de Groot , C A 2024 , ' Assessing the clinical benefit of systemic anti-cancer treatments in the Netherlands : The impact of different thresholds for effectiveness ' , European Journal of Cancer , vol. 202 , 114002 . https://doi.org/10.1016/j.ejca.2024.114002;
2024